New website aims to ease thyroid cancer treatment side effects
NCT ID NCT06853925
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a website designed to help thyroid cancer patients manage symptoms after radioactive iodine (RAI) treatment. About 88 adults who had RAI in the last three years will use either the new website or a standard one for four weeks. Researchers will check if the tool improves quality of life and is easy to use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 88 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2025
- Expected to finish
-
Feb 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18 or older (papillary or follicular carcinoma) * Diagnosed with differentiated thyroid cancer * Received radioactive iodine (RAI) treatment less than or equal to three years ago. * Mild to moderate symptoms of RAI * Able to provide informed consent in English * Access to a computer, tablet, or smartphone with internet connectivity Exclusion Criteria: * A condition that precludes providing informed consent or completing study procedures (cognitive or psychiatric condition, hearing problems) as identified by the patient's physician or as assessed by a trained study team member.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Differentiated thyroid cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The study's own enquiry address
This study publishes an address for enquiries. See it below .
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Georgetown University
RECRUITINGWashington D.C., District of Columbia, 20007, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Antibody-Drug conjugate targets TROP-2 in Hard-to-Treat thyroid cancers
- Can a targeted pill be safely used for RET-Driven cancers in india?
- Can a video keep thyroid cancer patients on track after surgery?
- Aortic graft used to rebuild windpipe in thyroid cancer surgery
- Radioactive antibody combo targets thyroid cancer
- Thyroid surgery under the microscope: what 3,000 real operations reveal